Key Points
- CEO Troy Wilson bought 101,119 Kura Oncology shares at an average $7.42 each, investing about $750,303 and increasing his stake by 18.92% to 635,456 shares. He also purchased 98,881 shares on November 13.
- Kura shares were reported down 8.8% and opened at $7.09, near their 52-week low of $6.75.
- The company’s latest quarterly loss per share of $0.78 was narrower than analysts’ $0.82 estimate, though revenue of $22.84 million fell short of expectations. Analysts’ consensus rating was “Moderate Buy,” with a $25.88 average price target.
Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) CEO Troy Wilson acquired 101,119 shares of the business's stock in a transaction dated Monday, November 16th. The stock was acquired at an average cost of $7.42 per share, with a total value of $750,302.98. Following the completion of the transaction, the chief executive officer owned 635,456 shares of the company's stock, valued at approximately $4,715,083.52. The trade was a 18.92% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Troy Edward Wilson also recently made the following trade(s):
- On Friday, November 13th, Troy Wilson bought 98,881 shares of Kura Oncology stock. The shares were acquired at an average price of $7.63 per share, with a total value of $754,462.03.
- On Monday, August 24th, Troy Wilson bought 100,000 shares of Kura Oncology stock. The shares were acquired at an average cost of $12.39 per share, for a total transaction of $1,239,000.00.
Kura Oncology Stock Down 8.8%
KURA opened at $7.09 on Tuesday. Kura Oncology, Inc. has a 1-year low of $6.75 and a 1-year high of $13.90. The stock's fifty day simple moving average is $10.05 and its 200 day simple moving average is $9.76. The company has a current ratio of 3.60, a quick ratio of 4.71 and a debt-to-equity ratio of 0.07. The stock has a market cap of $651.43 million, a PE ratio of -2.15 and a beta of 0.56.
Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.04. Kura Oncology had a negative return on equity of 336.24% and a negative net margin of 369.26%. The business had revenue of $22.84 million during the quarter, compared to the consensus estimate of $24.94 million. As a group, research analysts expect that Kura Oncology, Inc. will post -3.20 earnings per share for the current year.
Institutional Trading of Kura Oncology
Several institutional investors have recently added to or reduced their stakes in KURA. Jump Financial LLC lifted its holdings in shares of Kura Oncology by 738.8% during the third quarter. Jump Financial LLC now owns 372,409 shares of the company's stock worth $3,989,000 after buying an additional 328,009 shares in the last quarter. Bleakley Financial Group LLC acquired a new position in shares of Kura Oncology in the third quarter valued at about $228,000. Focus Advisor Solutions LLC acquired a new position in shares of Kura Oncology in the third quarter valued at about $286,000. Royce & Associates LP grew its stake in shares of Kura Oncology by 8.0% in the third quarter. Royce & Associates LP now owns 658,811 shares of the company's stock valued at $7,056,000 after acquiring an additional 48,826 shares in the last quarter. Finally, ACT Capital Partners L.P. bought a new position in Kura Oncology during the third quarter worth about $981,000.
Analyst Ratings Changes
Several equities analysts have recently weighed in on the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of Kura Oncology in a research report on Wednesday, October 14th. UBS Group set a $24.00 target price on shares of Kura Oncology in a report on Thursday. Wedbush upped their price target on shares of Kura Oncology from $36.00 to $38.00 and gave the company an "outperform" rating in a research note on Thursday, August 13th. Morgan Stanley set a $24.00 price target on shares of Kura Oncology in a report on Monday, August 24th. Finally, Deutsche Bank set a $24.00 price target on shares of Kura Oncology in a report on Wednesday, October 14th. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Kura Oncology currently has a consensus rating of "Moderate Buy" and a consensus price target of $25.88.
Read Our Latest Stock Report on Kura Oncology
About Kura Oncology
(
Get Free Report)
Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company's best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.
Further Reading

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].